ArticleBritish journal of cancer2015
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03577197 (Southeast Netherlands Advanced Breast Cancer Registry), which is not on this map. Cited by 119 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Southeast Netherlands Advanced Breast Cancer Registry
Who cites it
119 citing papers in PubMed.
- Exercise effects on lean body mass, muscle strength and functional performance in patients with metastatic breast cancer: the randomized controlled PREFERABLE-EFFECT study.Breast cancer research : BCR · 2026Trial
- Aggressive local therapy forOncology reports · 2023Trial
- Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.Breast cancer research and treatment · 2020Trial
- Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.Breast cancer research and treatment · 2018Trial
- Characteristics, treatment and survival in de novo and metachronous metastatic breast cancer: a nationwide comparative analysis.Breast cancer research and treatment · 2026Article
- Investigating initial patterns of progression on first-line treatment in patients with de novo metastatic breast cancer.Breast cancer research and treatment · 2026Review
- Prognostic Value of Baseline Sarcopenia and Adipose Tissue Indices in HR+/HER2- Metastatic Breast Cancer Treated with CDK4/6 Inhibitors: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study.Therapeutic advances in medical oncology · 2026Article
- Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study.Breast cancer (Dove Medical Press) · 2026Article
- Antibody-drug conjugates in the treatment of advanced triple-negative breast cancer.Przeglad menopauzalny = Menopause review · 2025Review
- First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data.Journal of clinical medicine · 2025Article
- Article
- Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review.JMIR research protocols · 2025Article
- 4-fluorophenylacetamide acetyl coumarin induces pro-inflammatory M1 macrophage polarization and suppresses the immunosuppressive M2 phenotype through PI3k/AKT/NF-κB modulation.Molecular biology reports · 2025Article
- Retrospective Case-Cohort Study on Risk Factors for Developing Distant Metastases in Women With Breast Cancer.Cancer medicine · 2025Article
- Metastasizing to the colon from triple-negative breast cancer: A case report and review of literature.World journal of gastrointestinal oncology · 2025Article
- Analysis of survival differences in advanced triple-negative breast cancer: a real-world study.Frontiers in oncology · 2025Article
- TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.Therapeutic advances in medical oncology · 2025Article
- Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset.Cancers · 2024Article
- Retrospective registry of patients with locally advanced/metastatic HRClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval, MFI) on the survival of metastatic breast cancer patients.
methodsConsecutive patients diagnosed with metastatic breast cancer in 2007-2009 in eight hospitals in the Southeast of the Netherlands were included and categorised based on MFI. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic impact of de novo metastatic breast cancer vs recurrent metastatic breast cancer (MFI ⩽24 months and >24 months), adjusted for age, hormone receptor and HER2 status, initial site of metastasis and use of prior (neo)adjuvant systemic therapy.
resultsEight hundred and fifteen patients were included and divided in three subgroups based on MFI; 154 patients with de novo metastatic breast cancer, 176 patients with MFI <24 months and 485 patients with MFI >24 months. Patients with de novo metastatic breast cancer had a prolonged survival compared with patients with recurrent metastatic breast cancer with MFI <24 months (median 29.4 vs 9.1 months, P<0.0001), but no difference in survival compared with patients with recurrent metastatic breast cancer with MFI >24 months (median, 29.4 vs 27.9 months, P=0.73). Adjusting for other prognostic factors, patients with MFI <24 months had increased mortality risk (hazard ratio 1.97, 95% CI 1.49-2.60, P<0.0001) compared with patients with de novo metastatic breast cancer. When comparing recurrent metastatic breast cancer with MFI >24 months with de novo metastatic breast cancer no significant difference in mortality risk was found. The association between MFI and survival was seen irrespective of use of (neo)adjuvant systemic therapy.
conclusionPatients with de novo metastatic breast cancer had a significantly better outcome when compared with patients with MFI <24 months, irrespective of the use of prior adjuvant systemic therapy in the latter group. However, compared with patients with MFI >24 months, patients with de novo metastatic breast cancer had similar outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.